Eloralintide (LY-3841136) is an amylin receptor agonist with human AMY1R EC 50 23.9 pM and human AMY3R EC 50 253.8 pM. Eloralintide induces decreased appetite, reduced food intake, body weight and fat mass loss, prolonged plasma calcium 2+ reduction, and weak conditioned taste avoidance. Eloralintide can be used for the research of obesity [1] [2] [3].
In Vivo, Eloralintide (0.1-300 nmol/kg; s.c.; single dose) dose-dependently reduces food intake and body weight in lean male Sprague-Dawley rats, with an ED50 of 3.7 nmol/kg for 96-hour food intake reduction[3]. Eloralintide (0.1-100 nmol/kg; s.c.; Q3D; 13-15 days) dose-dependently reduces food intake and body weight in diet-induced obese male Long Evans rats, primarily via fat mass loss, with an ED50 of 0.8 nmol/kg for fat mass loss[3].
In Vitro, Eloralintide acts as an agonist of both rat and human amylin receptors (AMYRs) and calcitonin receptors (CTRs)[2]. Eloralintide selectively activates human AMY1R (EC50 = 23.9 pM) with 11- to 12-fold greater potency than human AMY3R and CTR, and acts as a full agonist at all three human receptors[3]. Eloralintide binds human AMY1R (Ki = 478.1 pM) with 8-fold greater affinity than human AMY3R and CTR[3]. Eloralintide selectively activates rat AMY1R (EC50 = 5.4 pM) with 3-fold greater potency than rat AMY3R and 45-fold greater potency than rat CTR, and acts as a full agonist at all three rat receptors[3]. Eloralintide binds rat AMY1R (Ki = 48.1 pM) with 3-fold greater affinity than rat AMY3R and 109-fold greater affinity than rat CTR[3].
References:
[1]. Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. Published online January 20, 2026.
[2]. DAVID IPSEN, et al. 86-OR: The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels.
[3]. Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025 Dec;102:102271.
In Vivo, Eloralintide (0.1-300 nmol/kg; s.c.; single dose) dose-dependently reduces food intake and body weight in lean male Sprague-Dawley rats, with an ED50 of 3.7 nmol/kg for 96-hour food intake reduction[3]. Eloralintide (0.1-100 nmol/kg; s.c.; Q3D; 13-15 days) dose-dependently reduces food intake and body weight in diet-induced obese male Long Evans rats, primarily via fat mass loss, with an ED50 of 0.8 nmol/kg for fat mass loss[3].
In Vitro, Eloralintide acts as an agonist of both rat and human amylin receptors (AMYRs) and calcitonin receptors (CTRs)[2]. Eloralintide selectively activates human AMY1R (EC50 = 23.9 pM) with 11- to 12-fold greater potency than human AMY3R and CTR, and acts as a full agonist at all three human receptors[3]. Eloralintide binds human AMY1R (Ki = 478.1 pM) with 8-fold greater affinity than human AMY3R and CTR[3]. Eloralintide selectively activates rat AMY1R (EC50 = 5.4 pM) with 3-fold greater potency than rat AMY3R and 45-fold greater potency than rat CTR, and acts as a full agonist at all three rat receptors[3]. Eloralintide binds rat AMY1R (Ki = 48.1 pM) with 3-fold greater affinity than rat AMY3R and 109-fold greater affinity than rat CTR[3].
References:
[1]. Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. Published online January 20, 2026.
[2]. DAVID IPSEN, et al. 86-OR: The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels.
[3]. Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025 Dec;102:102271.